Hoth Therapeutics Inc (nasdaq:HOTH) Share Price

Company Profile

Business description
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Contact
1177 Avenue of the Americas
5th Floor, Suite 5066
New YorkNY10036
USA
T: +1 646 756-2997
https://www.hoththerapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,085.20	37.30	-0.41%
CAC 40	7,854.61	36.39	0.47%
DAX 40	23,674.53	315.35	1.35%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,228.11	32.45	0.35%
HKSE	26,576.59	138.08	0.52%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	44,752.32	149.95	-0.33%
NZX 50 Index	13,179.13	55.76	-0.42%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,797.60	50.90	-0.58%
SSE Composite Index	3,830.65	1.00	-0.03%